22 results about "Heparan sulfate" patented technology

Disclosed is a method of treating liver ischemia reperfusion (I / R) injury in a subject. In some aspects, the method comprises providing a subject suffering from liver I / R injury or at risk of suffering liver I / R injury; and administering to the subject one or more heparan sulfate (HS) compounds. In some aspects, the one or more HS compounds comprises about 5 to about 18 saccharide units, optionally about 12 to about 18 saccharide units. In some aspects, the one or more HS compounds comprises about 12 saccharide units.

The invention provides an application of OPO and a composition thereof in promoting intestinal development. The 1, 3-dioleoyl-2-palmitin disclosed by the invention can be used for up-regulating the transcriptional level of a coding gene gpc1 of phospholipid globulin glycan, a coding gene has1 of hyaluronic acid synthetase 1, a coding gene has2 of hyaluronic acid synthetase 2, a coding gene has3 of hyaluronic acid synthetase 3, a coding gene ext1 of exosome glycosyltransferase 1 and a coding gene ext2 of exosome glycosyltransferase 2; therefore, the development of a protein skeleton of the glycocalyx layer, the synthesis of hyaluronic acid and the synthesis of heparan sulfate are promoted, the development of the glycocalyx layer is further promoted, and the effects of improving the intestinal barrier, regulating the intestinal flora and improving the intestinal health are achieved.

The invention relates to the technical field of artificial design of enzymes, in particular to an artificial intelligence design and expression system construction method and system for lysosomal membrane protein type N-acetyltransferase with 11 transmembrane regions, and the method comprises the following steps: collecting reaction rate information of an enzyme and a substrate, associating a structure model with rate parameters, and comparing three-dimensional difference of residues, according to the method, by collecting the reaction rate correlation structure conformation, dynamic recognition of the key conformation state is achieved, the accuracy of three-dimensional space difference analysis is improved, host expression optimization factors are fused in the construction process, and the construction efficiency is improved. According to the method, the expression efficiency is improved, conformation function screening and structural stability parallel evaluation are carried out, the screening accuracy of efficient catalysis and stable expression is enhanced, three links of recognition, screening and construction are broken through, the target enzyme obtaining efficiency and expression quality are improved, and enzyme engineering is promoted to be developed towards high-throughput systematization.

This invention discloses a recombinant 2-O-sulfonyltransferase mutant and its preparation method, belonging to the field of biotechnology. The recombinant enzyme sequence is formed by fusing a truncated (E28~N356) mutant of hamster-derived 2-O-sulfonyltransferase (L119V-R188E-A240I) with an N-terminal maltose-binding protein (MBP) tag. The recombinant 2-O-sulfonyltransferase mutant exhibits higher activity, 1.9 times that of the recombinant wild type, and greater stability, retaining 86.6% of its activity after 5 days at room temperature. Furthermore, the soluble expression level of this recombinant mutant 2-O-sulfonyltransferase is increased by 5 times. This mutant, as a novel biocatalyst with high efficiency, stability, and controllable production costs, has significant application value and broad industrialization prospects in the industrial enzymatic synthesis of glycosaminoglycans such as heparin and heparan sulfate.

A major obstacle in the field of biotherapeutics is the need for platform technologies that enable high bioavailability and long-term therapeutic exposure of biotherapies in localized disease. Traditional approaches result in problematic trade-offs, such as toxicity and off-target side effects. The present disclosure provides compounds comprising follistatin domain 1 (FSD1) of follistatin (FST), which can bind to biological structures, such as the extracellular matrix, via heparan sulfate without the undesired neutralizing effects on the activity of activin A, myostatin, and GDF11, as full-length follistatin does. The present invention relates to fusion or conjugated proteins, compositions thereof, constructs or vectors encoding them, their medical uses, and methods for biotherapeutics.

The invention provides a preparation method and application of a dairy product for promoting development of an intestinal tract glycocalyx layer. Comprising a specific dose of casein phosphopeptides, and can up-regulate the transcriptional levels of a coding gene gpc1 of phospholipid globulin glycan, a coding gene has1 of hyaluronic acid synthetase 1, a coding gene has2 of hyaluronic acid synthetase 2, a coding gene has3 of hyaluronic acid synthetase 3, a coding gene ext1 of exosome glycosyltransferase 1 and a coding gene ext2 of exosome glycosyltransferase 2. Therefore, the development of a protein skeleton of the glycocalyx layer, the synthesis of hyaluronic acid and the synthesis of heparan sulfate are promoted, the development of the glycocalyx layer is further promoted, and the effects of improving the intestinal barrier, regulating the intestinal flora and improving the intestinal health are achieved.

The present invention relates to a pharmaceutical composition for preventing or treating Sanfilippo syndrome type A (MPS IIIA) comprising heparan N-sulfatase (HNS), and more particularly, to an optimal dose and period of administration of heparan N-sulfatase, which can effectively reduce the accumulation of heparan sulfate (HS) while improving the cognition of patients. According to the present invention, it can be used as enzyme replacement therapy (ERT) for treating Sanfilippo syndrome type A.

Enhanced recombinant adeno-associated viruses (rAAVs) (e.g., rAAV2, rAAVrh8R, etc.) are provided herein for improved gene therapy of eye or central nervous system (CNS) disorders, wherein the rAAV comprises one or more amino acid substitutions that interact with the heparan sulfate proteoglycan. The invention provides methods for enhancing retinal cell transduction and methods for treating eye diseases with enhanced compositions of rAAV particles. Furthermore, enhanced recombinant adeno-associated viruses (rAAVs) (e.g., rAAV2, rAAVrh8R, etc.) are provided herein for improved gene therapy of CNS disorders. The invention provides methods for delivering the rAAV to the CNS, methods for treating CNS disorders with enhanced compositions of rAAV particles, and kits for delivering the rAAV to the CNS and / or treating a CNS disorder.

The invention provides application of cheese protein zymolyte in promoting intestinal development. The casein zymolyte provided by the invention can up-regulate the transcriptional levels of a coding gene gpc1 of phospholipid globulin glycan, a coding gene has1 of hyaluronic acid synthetase 1, a coding gene has2 of hyaluronic acid synthetase 2, a coding gene has3 of hyaluronic acid synthetase 3, a coding gene ext1 of exosome glycosyltransferase 1 and a coding gene ext2 of exosome glycosyltransferase 2; therefore, the development of a protein skeleton of the glycocalyx layer, the synthesis of hyaluronic acid and the synthesis of heparan sulfate are promoted, the development of the glycocalyx layer is further promoted, and the effects of improving the intestinal barrier, regulating the intestinal flora and improving the intestinal health are achieved.

The invention provides application of casein phosphopeptides in promoting development of intestinal glycocalyx layers and preparing related products. The casein phosphopeptide provided by the invention can up-regulate the transcriptional level of a coding gene gpc1 of phospholipid globulin glycan, the transcriptional level of a coding gene has1 of hyaluronic acid synthetase 1, the transcriptional level of a coding gene has2 of hyaluronic acid synthetase 2, the transcriptional level of a coding gene has3 of hyaluronic acid synthetase 3, the transcriptional level of a coding gene ext1 of exosome glycosyltransferase 1 and the transcriptional level of a coding gene ext2 of exosome glycosyltransferase 2; therefore, the development of a protein skeleton of the glycocalyx layer, the synthesis of hyaluronic acid and the synthesis of heparan sulfate are promoted, the development of the glycocalyx layer is further promoted, and the effects of improving the intestinal barrier, regulating the intestinal flora and improving the intestinal health are achieved.

The invention provides formula milk powder as well as a preparation method and application thereof in promoting intestinal protection or repair. The formula milk powder disclosed by the invention comprises cheese protein zymolyte, and transcriptional levels of an encoding gene gpc1 capable of up-regulating phospholipid globulin glycan, an encoding gene has1 of hyaluronic acid synthetase 1, an encoding gene has2 of hyaluronic acid synthetase 2, an encoding gene has3 of hyaluronic acid synthetase 3, an encoding gene ext1 of exosome glycosyltransferase 1 and an encoding gene ext2 of exosome glycosyltransferase 2, therefore, the formation of a protein skeleton of a glycocalyx layer, the synthesis of hyaluronic acid and the synthesis of heparan sulfate are promoted, the formation of the glycocalyx layer is further promoted, and the effects of perfecting an intestinal barrier, regulating intestinal flora, improving intestinal health and promoting intestinal protection or repair are achieved.

The present invention relates to a lyophilized preparation containing, as an active ingredient, a fusion protein of an antibody and heparan N-sulfatase (SGSH), the lyophilized preparation further comprising an isotonic agent, a nonionic surfactant, and a buffering agent, wherein the nonionic surfactant contains polysorbate and poloxamer, and the buffering agent contains histidine.

The invention provides application of lactoferrin and a composition thereof in promoting intestinal development. The lactoferrin provided by the invention can up-regulate the transcriptional level of a coding gene gpc1 of phospholipid globulin glycan, the transcriptional level of a coding gene has1 of hyaluronic acid synthetase 1, the transcriptional level of a coding gene has2 of hyaluronic acid synthetase 2, the transcriptional level of a coding gene has3 of hyaluronic acid synthetase 3, the transcriptional level of a coding gene ext1 of exosome glycosyltransferase 1 and the transcriptional level of a coding gene ext2 of exosome glycosyltransferase 2; therefore, the development of a protein skeleton of the glycocalyx layer, the synthesis of hyaluronic acid and the synthesis of heparan sulfate are promoted, the development of the glycocalyx layer is further promoted, and the effects of improving the intestinal barrier, regulating the intestinal flora and improving the intestinal health are achieved.

Methods and compositions for diagnosing, preventing or treating a viral infection in a subject comprising administering to a subject in need thereof an effective amount of a glycosidase or a sulfatase to degrade a glycan, such as heparan sulfate, to inhibit viral infection, such as COVID-19. Methods for identifying a glycosidase, a sulfatase, or a microbe associated with increased susceptibility to viral infection in a subject.

The invention discloses a method for modifying mesenchymal stem cells with dual-response peptide fragments and application of the mesenchymal stem cells in drug delivery. The dual response type peptide fragment (MSP-Trap) is composed of three parts: a connecting sequence sensitive to matrix metalloproteinase, a binding sequence targeting heparan sulfate, and a functional group used for NHS coupling. The MSP-Trap peptide fragment can be coupled to the surface of a mesenchymal stem cell (MSC) through NHS, and can be used as a drug carrier to realize efficient delivery of drugs. According to the invention, the MSP-Trap-MSC is further combined with a drug to form a drug-MSP-Trap-MSC compound, so that the enrichment and delivery efficiency of the drug at a diseased region is enhanced, and the MSP-Trap-MSC compound is used for treating different types of diseases.

The present invention relates to heparan sulfate sugar mimetic compounds as heparan sulfate mimetics, and the use of these compounds as medicaments, cosmeceuticals and as molecular probes. The invention also relates to intermediate compounds useful in the preparation of various sugar mimetic compounds. The invention is particularly suitable for treating or preventing diseases such as cancer, inflammation, diabetic nephropathy, neurodegenerative diseases, for bone healing or wound healing, for cosmeceutical use, and as molecular probes comprising imaging agents.

The invention discloses a composite collagen dressing and a preparation method thereof, and relates to the technical field of composite collagen, the dressing comprises a body formed by a double-layer composite structure, and the double-layer composite structure comprises a chitosan fiber non-woven fabric layer and a functional layer. According to the invention, through compounding of collagen and regenerated cellulose, active crosslinking of heparan sulfate, and multiple technological innovations of a PCL drug-loaded microsphere and adhesive-free double-layer structure, the composite dressing which has excellent mechanical properties, an active repair function, long-acting drug sustained release and good biocompatibility is cooperatively constructed.

The application provides application of lactoferrin and a composition thereof in promoting intestinal development. The lactoferrin of the application can up-regulate the transcription level of a phospholipid globulin polysaccharide coding gene gpc1, a hyaluronic acid synthase 1 coding gene has1, a hyaluronic acid synthase 2 coding gene has2, a hyaluronic acid synthase 3 coding gene has3, an exosin glycosyltransferase 1 coding gene ext1 and an exosin glycosyltransferase 2 coding gene ext2, thereby promoting development of a protein skeleton of a glycocalyx layer, synthesis of hyaluronic acid, synthesis of heparan sulfate, further promoting development of the glycocalyx layer, and achieving the effects of perfecting an intestinal barrier, regulating intestinal flora and improving intestinal health.

It is provided a bioadhesive comprising an isolated extracellular matrix (ECM) from a decellularized organ with preserved (ultra) structure comprising laminins, collagen 4, collagen-6, collagen-1, fibronectin, elastin, fibrillin, ECM protein 1, proteoglycans, glycoproteins, biglycan, histidine rich glycoprotein, tenascin, and heparan sulfate proteoglycan 2. The bioadhesive described herein and provided composition can be used to seal intra-operative pulmonary air leaks after lung surgery.

The application provides application of casein phosphopeptide in promoting development of a sugar layer of an intestinal tract and preparation of related products. The casein phosphopeptide can up-regulate transcription levels of a coding gene gpc1 of phospholipid globulin polysaccharide, a coding gene has1 of hyaluronic acid synthetase 1, a coding gene has2 of hyaluronic acid synthetase 2, a coding gene has3 of hyaluronic acid synthetase 3, a coding gene ext1 of exosin glycosyltransferase 1 and a coding gene ext2 of exosin glycosyltransferase 2, thereby promoting development of a protein skeleton of the sugar layer, synthesis of hyaluronic acid and synthesis of heparan sulfate, further promoting development of the sugar layer, and achieving the effects of perfecting an intestinal tract barrier, regulating intestinal flora and improving intestinal health.

Disclosed herein are cellular derived heparin and heparan sulfate compositions, methods of making and using, and cell lines for making and using.

Provided herein are improved rAAV (e.g., rAAV2, rAAVrh8R, etc.) for enhanced gene therapy of ocular disorders or CNS disorders wherein the rAAV comprise one or more substitutions of amino acids that interact with heparan sulfate proteoglycan. The invention provides methods for improved transduction of retinal cells and methods for treating ocular diseases with improved compositions of rAAV particles. Further provided herein are improved recombinant adeno-associated virus (rAAV) (e.g., rAAV2, rAAVrh8R, etc.) for enhanced gene therapy of disorders of the CNS. The invention provides methods for delivering the rAAV to the CNS, methods for treating disorders of the CNS with improved compositions of rAAV particles, and kits for delivering the rAAV to the CNS and / or treating a CNS disorder.